Nuclear Medicine Software Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Nuclear medicine software refers to the platform and standalone tools used by hospitals, imaging centers, and research institutes to plan scans, reconstruct images, perform quantitative analysis, and integrate results into hospital PACS and electronic health records. The market is sized at approximately USD 0.97 billion in 2025 and is projected to grow at around 9.0% annually to roughly USD 1.49 billion by 2030. North America currently accounts for the largest share of revenue, while Asia-Pacific is the fastest-growing region as clinical infrastructure expands.

• •Estimated 2025 market value: ~USD 0.97 billion, with a 9.0% CAGR to ~USD 1.49 billion by 2030
• •Core use cases: oncology, cardiology, neurology imaging and theranostics dosimetry
• •Software is typically bundled with hybrid imaging systems or sold as standalone post-processing platforms

Rising cancer and cardiovascular disease prevalence is increasing the volume of PET and SPECT studies performed worldwide, which directly expands demand for acquisition and analysis software. The introduction of new therapeutic radiopharmaceuticals such as Lutetium-177 and Actinium-225 agents is driving adoption of dosimetry and treatment planning tools. At the same time, healthcare providers are upgrading to digital, AI-augmented imaging platforms to improve throughput, diagnostic accuracy, and regulatory compliance.

• •Expansion of theranostics and personalized radiopharmaceutical therapy workflows
• •Growing installed base of hybrid PET/CT, SPECT/CT, and PET/MR systems
• •Hospital investment in AI-based image reconstruction, quantification, and automated reporting

By software type, the market splits into imaging software (SPECT, PET, hybrid), treatment planning and dosimetry software, PACS/RIS integration solutions, and workflow or data management platforms. By application, oncology is the largest and fastest-growing segment, followed by cardiology and neurology. North America leads revenue due to high procedure volumes and reimbursement, while Asia-Pacific is the fastest-growing region on the back of new imaging centers in China, India, and Southeast Asia.

• •Application mix: oncology dominant, with growing neurology and cardiology demand
• •North America holds the largest regional share; Europe is mature and well-established
• •Asia-Pacific shows the highest growth rate as PET and SPECT capacity expands

What are the recent trends and outlook?

The near-term outlook points to steady mid-to-high single-digit-to-low double-digit growth as theranostics, AI, and cloud deployment reshape nuclear medicine workflows. AI-driven reconstruction, auto-segmentation, and quantitative reporting are expected to move from differentiators to standard requirements within the next few years. Over the longer term, integration of imaging software with radiopharmacy management, electronic patient records, and big-data analytics platforms is likely to define competitive positioning.

• •AI-based image reconstruction, quantification, and reporting becoming standard features
• •Cloud and SaaS delivery models replacing some on-premise deployments
• •Tightening integration between imaging software, treatment planning, and radiopharmacy systems